GlassScriptPhysician profile
Crispin J Semakula
NPI 1538107214
$34,410.95
in general payments reported to CMS, 2019-2025
29 companies · $83.92 in 2025
The $83.92 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $8,261 · 2021: $6,569 · 2022: $1,492 · 2023: $72.70 · 2024: $75.13 · 2025: $83.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $199 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $199.48 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19,654.25 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $13,556.11 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $321.32 | 2020-2021 | |
| Novo Nordisk INC | $106.00 | 2020-2023 | Ozempic |
| Recordati_rare_diseases_inc. | $73.89 | 2020-2025 | Isturisa |
| Abbott Laboratories | $65.01 | 2020-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $64.39 | 2020-2021 | |
| Lilly USA, LLC | $61.49 | 2019-2021 | |
| Organon LLC | $54.64 | 2022-2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $53.41 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.26 | 2020-2021 | |
| Insulet Corporation | $47.09 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $44.84 | 2020-2021 | |
| Glaxosmithkline, LLC. | $37.27 | 2024-2025 | Shingrix, Arexvy |
| Redhill Biopharma INC. | $24.20 | 2024 | Talicia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $18.86 | 2021 | |
| Phadia US INC. | $18.77 | 2024 | Immunocap |
| Intuity Medical INC | $17.63 | 2022 | |
| Lifescan, INC. | $16.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.78 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.67 | 2021 | |
| Botanix Sb INC | $14.44 | 2025 | Sofdra |
| Esperion Therapeutics, INC. | $14.27 | 2024 | Nexletol |
| Companion Medical, INC. | $14.18 | 2020 | |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 | |
| Shire North American Group INC | $12.55 | 2019 | |
| Almatica Pharma LLC | $11.75 | 2022 | |
| Cequr Corporation | $7.59 | 2023 | Cequr Simplicity |
| Beta Bionics, INC. | $4.69 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crispin Semakula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.